IceCure Medical Expands U.S. Clinical Trial for Cryoablation Breast Cancer Treatment
Event summary
- Adventist Health Glendale becomes the first U.S. clinical site to enroll patients in IceCure Medical's post-marketing ChoICE Study for low-risk breast cancer cryoablation treatment.
- The study aims to enroll up to 400 patients across 30 U.S. sites, gathering real-world data to support broader clinical adoption of ProSense®.
- Dr. Dennis Holmes, a recognized leader in breast cancer cryoablation, will lead the site at Adventist Health Glendale.
- ProSense® received FDA marketing authorization in October 2025 for the local treatment of low-risk breast cancer in patients aged 70 and above.
The big picture
IceCure Medical's expansion of its ChoICE Study into Adventist Health Glendale marks a strategic move to bolster real-world evidence for its cryoablation technology. This aligns with broader industry trends toward minimally invasive cancer treatments and the growing emphasis on patient-specific, low-risk options. The study's success could significantly enhance ProSense®'s market position, particularly as it competes with more invasive surgical procedures.
What we're watching
- Clinical Adoption
- How the real-world data from the ChoICE Study will influence broader adoption of ProSense® in U.S. clinical practice.
- Regulatory Dynamics
- Whether the FDA's marketing authorization and the study's outcomes will pave the way for expanded indications or reimbursement policies.
- Competitive Positioning
- The pace at which IceCure Medical can establish ProSense® as a preferred minimally invasive option against traditional surgical methods.
Related topics